Human vascular progenitor cells (green), made from Zambidis’ lab-grown naive stem cells, engraft into blood vessels (red) in a mouse retina. Credit: Elias Zambidis, Johns Hopkins Medicine
Johns Hopkins Medicine scientists say they have successfully turned back the biological hands of time, coaxing adult human cells in the laboratory to revert to a primitive state, and unlocking their potential to replace and repair damage to blood vessels in the retina caused by diabetes.
The findings from this experimental study, they say, advance regenerative medicine techniques aimed at reversing the course of diabetic retinopathy and other blinding eye diseases.
“Our study results bring us a step closer to using stem cells more widely in regenerative medicine, without the historical problems our field has encountered in getting such cells to differentiate and avoid becoming cancerous,” says Elias Zambidis, M.D., Ph.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center and a member of Johns Hopkins’ Institute for Cell Engineering.
Results of experiments using human cells and mice were published online March 5 in Nature Communications.
According to the National Eye Institute, diabetic retinopathy is a leading cause of blindness in U.S. adults. By 2050, researchers estimate that some 14.6 million Americans will have the condition, which results in abnormal blood vessel growth in the retina, where light is processed into vision.
For the study, the scientists began their experiments with a fibroblast — a connective tissue cell — taken from a person with type 1 diabetes. Reprogrammed fibroblasts function as “stem” cells, with the potential to give rise to all tissues in the body, including blood vessels.
The Johns Hopkins team, including research associate Tea Soon Park, Ph.D., reprogrammed the fibroblast stem cells to revert to a state that is even more primitive than that of conventional human induced pluripotent stem cells — more like the state of embryonic cells about six days after fertilization. This is when cells are the most “naive,” or more capable of developing into any specialized type of cell with a much higher efficiency than conventional human induced pluripotent stem cells.
To do this, the scientists bathe the cells in a cocktail of nutrients and chemicals. What should go into the cocktail to build a better naive stem cell has been a subject of debate over the past decade.
Zambidis’ team used a cocktail mixture of two drugs that other scientists previously used to reprogram stem cells: GSK3? inhibitor CHIR99021, which blocks carbohydrate storage in cells, and MEK inhibitor PD0325901, an experimental anti-cancer drug that can block cancer cell growth. The team had also looked at the potential of a third drug, a PARP inhibitor — a popular anticancer drug used to treat a variety of cancers including those of the ovaries and breast.
To the researchers’ surprise, Zambidis says, the trifecta of MEK, GSK3? and PARP inhibitors worked to wind back the cells’ biological clock. He calls the cocktail 3i, named for the three inhibitors. Zambidis’ team had first reported experiments using the three-drug cocktail in 2016.
For the new study, the research team tracked the reprogrammed stem cells’ molecular profile, including measures of proteins such as NANOG, NR5A2, DPPA3 and E-cadherin that guide cell differentiation. That profile appeared similar to that found in so-called naive epiblast cells, the primitive cells that make up an approximately six day-old human embryo.
The scientists also found that the stem cells reprogrammed with the 3i cocktail did not have abnormal changes in factors that can alter core DNA, called epigenetics, that typically plague other lab-made versions of naive stem cells.
Finally, the research team injected cells called vascular progenitors, which were made from the naive stem cells and are capable of making new blood vessels, into the eyes of mice bred to have a form of diabetic retinopathy that results from blood vessels closing off in the retina. They found that the naive vascular progenitors migrated into the retina’s innermost tissue layer that encircles the eye, with higher efficiencies than have been reported with vascular cells made from conventional stem cell approaches. The naive vascular cells took root there, and most survived in the retina for the duration of the four-week study.
“Interestingly, the 3i ‘naive reprogramming’ cocktail appeared to erase disease-associated epigenetics in the donor cells, and brought them back to a healthy, pristine non-diabetic stem cell state,” says Zambidis.
For comparison, the team reprogrammed diabetic fibroblasts to non-naive stem cells using standard methods, and the resulting vascular progenitor cells failed to migrate as deeply into the retina or survive the length of the study.
Zambidis, Park and the other research team members say more experiments are needed to refine the 3i cocktail and to study the regenerative capacity of the stem cells they grow from the cocktail.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Regenerative medicine techniques
- Three New Degrees Approved, Including Ph.D. in Regenerative Medicineon October 5, 2020 at 7:49 am
The Board of Trustees has approved three new degrees, including a doctorate in the medical field and a master’s in the accounting field. The new ...
- Wellward Regenerative Medicine Offers Cutting Edge Sports Medicine Program to Speed Up Recovery Time and Reduce Athletic Injurieson October 1, 2020 at 9:44 pm
Oct. 1, 2020 /PRNewswire-PRWeb/ -- Wellward Regenerative Medicine, leading provider of regenerative ... look into patients' medical histories and examine the body using novel techniques like live, ...
- Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Countryon October 1, 2020 at 5:47 am
The market growth is primarily attributed to the increasing incidences of chronic diseases, road accidents, and trauma injuries, and technological advancements in 3D tissue engineering techniques.High ...
- Orgenesis Announces Agreement to Acquire Koligo Therapeutics, a Leader in Personalized Cell ...on September 29, 2020 at 3:30 am
Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®, a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis ...
- I had the opportunity to get first-hand experience in conducting and managing my own researchon September 27, 2020 at 5:28 pm
Alongside the taught aspects of the course, I was able to complete a lab project within the department. Here I had the opportunity to get first-hand experience in conducting an ...
Go deeper with Google Headlines on:
Regenerative medicine techniques
Go deeper with Bing News on:
- More Fijians lose eyesight to diabetes: local mediaon October 7, 2020 at 1:28 am
There are rising concerns that Fijians are losing their eyesight to diabetes as more than 550 people suffering from diabetic retinopathy have visited the Pacific Eye Institute this year to test their ...
- As We Fight The Coronavirus Pandemic, We Cannot Ignore Non-Communicable Diseaseson October 6, 2020 at 3:13 pm
As the world’s attention stays riveted on the coronavirus pandemic, non-communicable diseases (NCDs) are silently wreaking havoc. Millions of people with NCDs are struggling to get the care they need ...
- New treatment could reverse vision loss caused by retinopathyon October 6, 2020 at 4:38 am
Researchers have developed an experimental compound that could treat vision loss in premature infants and adults.
- Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200on October 6, 2020 at 4:30 am
Under this agreement, Kemwell will manage all CMC and clinical manufacturing activities as well as provide OCU200 supplies for IND-enabling toxicology studies and Phase 1/2a clinical trials. Kemwell ...
- The Impact of Diabetes on Your Eyeson October 6, 2020 at 3:36 am
Diabetes is a condition wherein blood glucose levels are abnormally high. Consistently high glucose levels cause damage to various organs of the human body in the long run. 'Diabetic Retinopathy' is ...